Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Gabapentin NDC 64725-0138 by Tya Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label Image - 64725 0138

Label Image - 64725 0138

This is a description of a medication called Gabapentin, in the form of 300mg capsules. The medication comes in a bottle package containing 30 capsules. The manufacturer of the medication is Sun Pharmaceuticals, and it was packaged by T.Y.A. Pharmaceuticals located in Tallahassee, Florida. The bottle has a lot number of X0 and an expiration date of XX-XX-XX. The medication comes with an insert detailing the appropriate dosage, as it is not mentioned here.*

gabapentin-fig01 - gabapentin fig01

gabapentin-fig01 - gabapentin fig01

The text describes a graph showing weekly pain scores for a study with a dose titration period and a fixed dose period, comparing a placebo to a 3600 mg/day dose of Gabapentin. The graph displays a statistical significance level of p<0.01.*

gabapentin-fig02 - gabapentin fig02

gabapentin-fig02 - gabapentin fig02

The text describes a study on the effectiveness of Gabapentin in reducing pain. The study involved a 3-week dose titration period followed by a 4-week fixed dose period where patients were given either a placebo or Gabapentin in doses of 1800mg or 2400mg per day. The results of the study are shown in Figure 2 which displays weekly mean pain scores. It appears that Gabapentin, particularly in a dose of 2400mg per day, reduced pain significantly compared to the placebo group.*

gabapentin-fig03 - gabapentin fig03

gabapentin-fig03 - gabapentin fig03

The text describes the results of controlled postherpetic neuralgia (PHN) studies evaluating the percentage of patients with >50% reduction in pain score (i.e., responders) at endpoint for placebo (PBO) and gabapentin (GBP) treatment groups. The results are presented in Figure 3, with data from two separate studies, Study 1 and Study 2, shown for the GBP treatment group. The significance levels of the differences between the treatment groups are indicated with asterisks, with ***p<0.001 indicating a highly significant difference and **p<0.01 indicating a significant difference.*

gabapentin-fig04 - gabapentin fig04

gabapentin-fig04 - gabapentin fig04

This appears to be a description of a figure, possibly related to a study on Gabapentin as an adjunctive therapy for patients over 12 years of age with partial seizures. The figure shows the responder rates expressed as a difference from placebo by dose and study. The x-axis has values of 600, 900, 1200, and 1800 for daily dose in mg. The text does not provide any additional information about the study or its results.*

gabapentin-structure - gabapentin structure

gabapentin-structure - gabapentin structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.